RxDoctor Payments Data

Syed Rasheed, MD

Psychiatry · Paramus, NJNPI 1669511036

Payments from drug & device makers

$3,922in general payments, 2019–2025

Across 257 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$443
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$420
  • Supernus Pharmaceuticals, Inc.$345
  • Neurocrine Biosciences, Inc.$341
  • Otsuka America Pharmaceutical, Inc.$311
  • AbbVie$291
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$3,915100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,922 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$52,343
Medicare patients
70
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trazodone Hcl35$416
Aripiprazole16$386
Bupropion XlBupropion Hcl16$346
Escitalopram Oxalate32$318
Venlafaxine Hcl ErVenlafaxine Hcl20$262
Alprazolam29$253
Amitriptyline Hcl15$235
Buspirone Hcl21$212
Sertraline Hcl17$181
Gabapentin12$173
Duloxetine Hcl15$161
Citalopram HbrCitalopram Hydrobromide15$158
Paroxetine Hcl18$151
Risperidone16$151
Clonazepam13$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$41$18117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →